167 related articles for article (PubMed ID: 35354691)
1. Increased PD-L1 Expression in Acquired Cisplatin-Resistant Lung Cancer Cells via Mir-181a.
Chen Y; Song W; Gao Y; Dong X; Ji X
Tohoku J Exp Med; 2022 May; 257(1):33-43. PubMed ID: 35354691
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.
Zhang P; Ma Y; Lv C; Huang M; Li M; Dong B; Liu X; An G; Zhang W; Zhang J; Zhang L; Zhang S; Yang Y
Cancer Sci; 2016 Nov; 107(11):1563-1571. PubMed ID: 27581532
[TBL] [Abstract][Full Text] [Related]
3. Circular RNA hsa_circ_0068252 Functions in Cisplatin Resistance and Immune Response via miR-1304-5p/PD-L1 Axis in Non-Small Cell Lung Cancer.
Li J; Xu J; Wu G; Ren Y; Wang X; Zhang Q
Chemotherapy; 2022; 67(4):223-233. PubMed ID: 35649347
[TBL] [Abstract][Full Text] [Related]
4. miR-181a and miR-630 regulate cisplatin-induced cancer cell death.
Galluzzi L; Morselli E; Vitale I; Kepp O; Senovilla L; Criollo A; Servant N; Paccard C; Hupé P; Robert T; Ripoche H; Lazar V; Harel-Bellan A; Dessen P; Barillot E; Kroemer G
Cancer Res; 2010 Mar; 70(5):1793-803. PubMed ID: 20145152
[TBL] [Abstract][Full Text] [Related]
5. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
Wang H; Fu C; Du J; Wang H; He R; Yin X; Li H; Li X; Wang H; Li K; Zheng L; Liu Z; Qiu Y
J Exp Clin Cancer Res; 2020 Feb; 39(1):29. PubMed ID: 32024543
[TBL] [Abstract][Full Text] [Related]
6. Arsenic sulfide reverses cisplatin resistance in non-small cell lung cancer in vitro and in vivo through targeting PD-L1.
Tian W; Sun Y; Cheng Y; Ma X; Du W; Shi W; Guo Q
Thorac Cancer; 2021 Oct; 12(19):2551-2563. PubMed ID: 34469060
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-4458 Regulates PD-L1 Expression to Enhance Anti-tumor Immunity in NSCLC via Targeting STAT3.
Liu W; Liu R; Yuan R; Wang X
Mol Biotechnol; 2021 Dec; 63(12):1268-1279. PubMed ID: 34386930
[TBL] [Abstract][Full Text] [Related]
8. MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC.
Xie WB; Liang LH; Wu KG; Wang LX; He X; Song C; Wang YQ; Li YH
Cell Physiol Biochem; 2018; 46(2):654-663. PubMed ID: 29617683
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells.
Sheng Q; Zhang Y; Wang Z; Ding J; Song Y; Zhao W
Clin Exp Immunol; 2020 Apr; 200(1):45-52. PubMed ID: 31821542
[TBL] [Abstract][Full Text] [Related]
11. Loss of Scribble confers cisplatin resistance during NSCLC chemotherapy via Nox2/ROS and Nrf2/PD-L1 signaling.
Wang N; Song L; Xu Y; Zhang L; Wu Y; Guo J; Ji W; Li L; Zhao J; Zhang X; Zhan L
EBioMedicine; 2019 Sep; 47():65-77. PubMed ID: 31495720
[TBL] [Abstract][Full Text] [Related]
12. Decreased MicroRNA-26a expression causes cisplatin resistance in human non-small cell lung cancer.
Yang Y; Zhang P; Zhao Y; Yang J; Jiang G; Fan J
Cancer Biol Ther; 2016 May; 17(5):515-25. PubMed ID: 26492332
[TBL] [Abstract][Full Text] [Related]
13. microRNA-381 suppresses the growth and increases cisplatin sensitivity in non-small cell lung cancer cells through inhibition of nuclear factor-κB signaling.
Huang RS; Zheng YL; Zhao J; Chun X
Biomed Pharmacother; 2018 Feb; 98():538-544. PubMed ID: 29287202
[TBL] [Abstract][Full Text] [Related]
14. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
15. miR-526b-3p inhibits lung cancer cisplatin-resistance and metastasis by inhibiting STAT3-promoted PD-L1.
Chen KB; Yang W; Xuan Y; Lin AJ
Cell Death Dis; 2021 Jul; 12(8):748. PubMed ID: 34321456
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer.
Fournel L; Wu Z; Stadler N; Damotte D; Lococo F; Boulle G; Ségal-Bendirdjian E; Bobbio A; Icard P; Trédaniel J; Alifano M; Forgez P
Cancer Lett; 2019 Nov; 464():5-14. PubMed ID: 31404614
[TBL] [Abstract][Full Text] [Related]
17. Circ_0072088 knockdown contributes to cisplatin sensitivity and inhibits tumor progression by miR-944/LASP1 axis in non-small cell lung cancer.
Zhang L; Wu Y; Hou C; Li F
J Gene Med; 2022 May; 24(5):e3414. PubMed ID: 35106879
[TBL] [Abstract][Full Text] [Related]
18. Acacetin inhibited non-small-cell lung cancer (NSCLC) cell growth via upregulating miR-34a in vitro and in vivo.
Li J; Zhong X; Zhao Y; Shen J; Xiao Z; Pilapong C
Sci Rep; 2024 Jan; 14(1):2348. PubMed ID: 38287075
[TBL] [Abstract][Full Text] [Related]
19. Apigenin Enhanced Antitumor Effect of Cisplatin in Lung Cancer via Inhibition of Cancer Stem Cells.
Li Y; Chen X; He W; Xia S; Jiang X; Li X; Bai J; Li N; Chen L; Yang B
Nutr Cancer; 2021; 73(8):1489-1497. PubMed ID: 32757802
[TBL] [Abstract][Full Text] [Related]
20. DLX6-AS1 activated by H3K4me1 enhanced secondary cisplatin resistance of lung squamous cell carcinoma through modulating miR-181a-5p/miR-382-5p/CELF1 axis.
Zhao X; Wang J; Zhu R; Zhang J; Zhang Y
Sci Rep; 2021 Oct; 11(1):21014. PubMed ID: 34697393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
